DDInter1628 DDInter860
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier. Transmission of the virus occurs through percutaneous contact with contaminated blood, serum or plasma. Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen. There is no specific treatment for hepatitis. The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. Viral hepatitis caused by hepatitis B virus is a major worldwide health problem, though the incidence and epidemiology vary widely among geographical areas and population subgroups. In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier state). Certain population subgroups in these areas, however, are at high risk (see Indications and Clinical Use). In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%. It is estimated that the reservoir of persistent hepatitis B surface antigen carriers amounts to 350 million people worldwide. Carriers are at a high risk of developing chronic liver disease which may lead to cirrhosis or primary hepatocellular carcinoma. A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6 to14 years following a nationwide hepatitis B vaccination in Taiwan. This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma. Vaccination against hepatitis B is expected in the long term to reduce the overall incidence of both hepatitis B and the chronic complications such as chronic active hepatitis and cirrhosis.
Ruxolitinib {u} (Compound) downregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib {u} (Compound) downregulates {v} (Gene) POLE2
POLE2 {u} (Gene) is bound by {v} (Compound) Cladribine
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib {u} (Compound) downregulates {v} (Gene) POLE2
POLE2 {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cladribine (Compound) and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) downregulates POLE2 (Gene) and POLE2 (Gene) is bound by Cladribine (Compound) and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) downregulates POLE2 (Gene) and POLE2 (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Cladribine (Compound) and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Etoposide (Compound) and PTGS2 (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)